Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Abstract: Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, w...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2018-04-01
coleção:	Blood Advances
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2473952920310375
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!